ACTA1 and cardiac hypertrophy: Moreover, Selumetinib attenuated the over-expression of cardiac hypertrophy markers, including β-MHC, ANP and α-SMA (Fig 7D) as well as prevented cardiac fibrosis caused by AAC pressure overload (Fig 7C).